All articles
How Insurance and GLP 1 Drug Shortages Are Increasing Interest in Compounded Medications
Reading time:
6 min
Weight loss
Get expert guidance and a personalized care plan designed around you.
Why Patients Gravitate Toward Compounded Options
Many people who turned to compounded GLP 1s described the experience as smoother and more predictable. The cost was often lower and more stable. Communication was more direct, and refills were processed more quickly than at large national pharmacy chains. Patients who relied on mail order options often found compounded GLP 1s easier to receive on time.
For people already dealing with complex chronic health needs, consistency and predictability matter. Some patients also expressed that working with a telehealth program connected to a reputable compounding pharmacy felt safer than trying to navigate online sellers offering questionable products. When done responsibly, compounding can serve a legitimate role for certain patients, especially when access to an approved drug is limited.
FDA Safety Concerns and Evolving Regulations
While compounded GLP 1s helped many people during the shortage, regulators have raised important concerns. Some compounders used semaglutide salt forms that were different from the active ingredient studied in clinical trials. Standardization varied widely between pharmacies. Because these compounded versions are not FDA approved, potency and purity are not guaranteed in the same way they are for branded medications.
The FDA issued warnings in 2024 and 2025 to clarify that compounded GLP 1s should be used only when an FDA approved product is not available or when a patient genuinely cannot use the approved product for specific medical reasons. As branded supply has improved, the FDA has begun reducing the allowances that were granted during the shortage. Some compounded products that were permitted before may no longer be allowed moving forward (U.S. Food and Drug Administration, 2024; 2025).
What Compounding Will Look Like Going Forward
Compounding is not disappearing. It will continue to play an important role for patients who need custom formulations or cannot tolerate certain inactive ingredients. It may also remain relevant during temporary shortages or specific situations where FDA approved options are unavailable. However, the landscape is shifting toward tighter oversight, more scrutiny, and clearer rules.
Responsible clinical programs will treat compounding as one option within a broader treatment toolkit. Safety, transparency, and pharmacy quality must remain priorities. Patients benefit most when a licensed clinician helps determine whether a compounded option is appropriate and ensures that the pharmacy involved meets high safety standards.
If you are trying to decide which path makes sense for your situation, a structured program like Mochi Health can help guide you.
FAQs: Compounding, Insurance, and Access
Are compounded GLP 1s FDA approved?
No. Compounded medications are not FDA approved. They do not go through the same approval process as branded drugs and are prepared on a patient by patient basis.
Are compounded GLP 1s cheaper?
Many patients have found them more affordable than paying cash for a branded product without insurance, although prices vary depending on the pharmacy.
Why did compounded GLP 1s become popular?
Patients were drawn to them because of pharmacy shortages, high branded medication prices, strict insurance rules, and the desire for more predictable access.
Are compounded medications still allowed now that shortages are improving?
Some types are being phased out. The continued availability of certain compounded GLP 1s depends on the medication, the dosage form, and the current FDA shortage status.
Check Your Eligibility
If you are interested in GLP 1 treatment or want to learn whether compounded semaglutide is an option for you, you can start by completing Mochi’s simple eligibility questionnaire. It only takes a few minutes and helps our clinical team understand your goals, medical history, and the safest path forward. Every patient receives personalized guidance, clear information about medication options, and support throughout their care. You can begin your eligibility check today and take the first step toward consistent, accessible, and dependable obesity treatment with Mochi. Check your eligibility
References:
KFF. (2024). KFF Health Tracking Poll: The public’s use and views of GLP 1 drugs.
U.S. Food and Drug Administration. (2024). FDA’s concerns with unapproved GLP 1 drugs used for weight loss.
U.S. Food and Drug Administration. (2025). Clarifying policies for compounders as national GLP 1 supply stabilizes.
Share this post
Weight loss
More articles
Read next
For iOS & Android
